Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, et al. Nat Med 2024;30:1330-1338.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, et al. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nat Med 2024;30:1330-1338.
PMID: 38653864